Celebrate Swine Flu Scare
With Windfall Profits
“With a pandemic like this, the upside for us is clearly significant,’’ said Andrin Oswald, chief executive of Cambridge-based Novartis Vaccines and Diagnostics, a unit of the Swiss pharmaceutical giant.
For a handful of drug makers, including the Novartis AG vaccine division in Cambridge, the global effort to combat the swine flu is turning out to be good business, bringing them a $7 billion windfall.